Member
Since
3
Yrs
Mylan Technologies Inc.
110 Lake Street
St. Albans, Vermont-05478, USA
Contact Supplier
FOB Price : Get Latest Price

somerset pharmaceuticals, inc. , a wholly owned subsidiary of mylan inc. ,
received approval from the fda for emsam® transdermal
selegiline, on february 27 of 2006. Emsam® is the
first transdermal treatment for major depressive disorder. All aspects of the
emsam® product related to its design, chemistry,
manufacturing and controls were the result of the integration of the talents
and expertise of mti scientists. Emsam® is
manufactured by mti.


antidepressants increased the risk of suicidal thinking and behavior
(suicidality) in short-term studies in children and adolescents with major
depressive disorder (mdd) and other psychotic disorders. Anyone considering the
use of emsam® or other antidepressants in a child or
adolescent must balance this risk with the clinical need.


emsam® is not indicated for use in pediatric patients.


for additional details please see full prescribing information, including boxed
warnings.

Send Enquiry




 
More Products From This Supplier
 
 
Recommended Product
 
 

sending enquiry
Thank You Close X
You may also visit more related suppliers as given below :

unable to instantiate your call right now. please try after some time.

close

© Copyright HelloTrade.com